EP 3979789 A1 20220413 - TREATMENT OF SAPROLEGNIASIS
Title (en)
TREATMENT OF SAPROLEGNIASIS
Title (de)
BEHANDLUNG VON SAPROLEGNIA
Title (fr)
TRAITEMENT DE SAPROLÉGNIOSE
Publication
Application
Priority
- SE 1950670 A 20190605
- SE 2020050468 W 20200507
Abstract (en)
[origin: WO2020246927A1] A compound for use in the treatment of saprolegniasis in an aquatic animal is provided, in which the compound is an inhibitor of a non-homologous essential protein in Saprolegnia. The non-homologous essential protein is essential for a Saprolegnia oomycete and is not homologous to any protein in the proteome of the aquatic animal. The compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
IPC 8 full level
A01K 61/13 (2017.01); A61K 31/10 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/194 (2006.01); A61K 31/42 (2006.01)
CPC (source: EP)
A61K 31/16 (2013.01); A61K 31/165 (2013.01); A61K 31/20 (2013.01); A61K 31/635 (2013.01); A01K 61/13 (2016.12)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020246927 A1 20201210; CA 3142601 A1 20201210; CN 114007414 A 20220201; EP 3979789 A1 20220413; EP 3979789 A4 20220810
DOCDB simple family (application)
SE 2020050468 W 20200507; CA 3142601 A 20200507; CN 202080045424 A 20200507; EP 20818734 A 20200507